Connect with us

TOP SCEINCE

New gene delivery vehicle shows promise for human brain gene therapy

Published

on

New gene delivery vehicle shows promise for human brain gene therapy


In an important step toward more effective gene therapies for brain diseases, researchers from the Broad Institute of MIT and Harvard have engineered a gene-delivery vehicle that uses a human protein to efficiently cross the blood-brain barrier and deliver a disease-relevant gene to the brain in mice expressing the human protein. Because the vehicle binds to a well-studied protein in the blood-brain barrier, the scientists say it has a good chance at working in patients.

Gene therapy could potentially treat a range of severe genetic brain disorders, which currently have no cures and few treatment options. But FDA-approved forms of the most commonly used vehicle for packaging and delivering these therapies to target cells, adeno-associated viruses (AAVs), aren’t able to efficiently cross the blood-brain barrier at high levels and deliver therapeutic cargo. The enormous challenge of getting therapies past this barrier — a highly selective membrane separating the blood from the brain — has stymied the development of safer and more effective gene therapies for brain diseases for decades.

Now researchers in the lab of Ben Deverman, an institute scientist and senior director of vector engineering at the Broad, have engineered the first published AAV that targets a human protein to reach the brain in humanized mice. The AAV binds to the human transferrin receptor, which is highly expressed in the blood-brain barrier in humans. In a new study published in Science, the team showed that their AAV, when injected into the bloodstream in mice expressing a humanized transferrin receptor, crossed into the brain at much higher levels than the AAV that is used in an FDA-approved gene therapy for the central nervous system, AAV9. It also reached a large fraction of important types of brain cells, including neurons and astrocytes. The researchers then showed that their AAV could deliver copies of the GBA1 gene, which has been linked to Gaucher’s disease, Lewy body dementia, and Parkinson’s disease, to a large fraction of cells throughout the brain.

The scientists add that their new AAV could be a better option for treating neurodevelopmental disorders caused by mutations in a single gene such as Rett syndrome or SHANK3 deficiency; lysosomal storage diseases like GBA1deficiency; and neurodegenerative diseases such as Huntington’s disease, prion disease, Friedreich’s ataxia, and single-gene forms of ALS and Parkinson’s disease.

“Since we came to the Broad we’ve been focused on the mission of enabling gene therapies for the central nervous system,” said Deverman, senior author on the study. “If this AAV does what we think it will in humans based on our mouse studies, it will be so much more effective than current options.”

“These AAVs have the potential to change a lot of patients’ lives,” said Ken Chan, a co-first author on the paper and group leader from Deverman’s group who has been working on solving gene delivery to the central nervous system for nearly a decade.

Mechanism first

For years, researchers developed AAVs for specific applications by preparing massive AAV libraries and testing them in animals to identify top candidates. But even when this approach succeeds, the candidates often don’t work in other species, and the approach doesn’t provide information about how the AAVs reach their targets. This can make it difficult to translate a gene therapy using these AAVs from animals to humans.

To find a delivery vehicle with a greater chance of reaching the brain in people, Deverman’s team switched to a different approach. They used a method they published last year, which involves screening a library of AAVs in a test tube for ones that bind to a specific human protein. Then they test the most promising candidates in cells and mice that have been modified to express the protein.

As their target, the researchers chose human transferrin receptor, which has long been the target of antibody-based therapies that aim to reach the brain. Several of these therapies have shown evidence of reaching the brain in humans.

The team’s screening technique identified an AAV called BI-hTFR1 that binds human transferrin receptor, enters human brain cells, and bypasses a human cell model of the blood-brain barrier.

“We’ve learned a lot from in vivo screens but it has been tough finding AAVs that worked this well across species,” added Qin Huang, a co-first author on the study and a senior research scientist in Deverman’s lab who helped develop the screening method to find AAVs that bind specific protein targets. “Finding one that works using a human receptor is a big step forward.”

Beyond the dish

To test the AAVs in animals, the researchers used mice in which the mouse gene that encodes the transferrin receptor was replaced with its human equivalent. The team injected the AAVs into the bloodstream of adult mice and found dramatically higher levels of the AAVs in the brain and spinal cord compared to mice without the human transferrin receptor gene, indicating that the receptor was actively ferrying the AAVs across the blood-brain barrier.

The AAVs also showed 40-50 times higher accumulation in brain tissue than AAV9, which is part of an FDA-approved therapy for spinal muscular atrophy in infants but is relatively inefficient at delivering cargo to the adult brain. The new AAVs reached up to 71 percent of neurons and 92 percent of astrocytes in different regions of the brain.

In work led by research scientist Jason Wu, Deverman’s team also used the AAVs to deliver healthy copies of the human GBA1 gene, which is mutated in several neurological conditions. The new AAVs delivered 30 times more copies of the GBA1 gene than AAV9 in mice and were delivered throughout the brain.

The team said that the new AAVs are ideal for gene therapy because they target a human protein and have similar production and purification yields as AAV9 using scalable manufacturing methods. A biotech company co-founded by Deverman, Apertura Gene Therapy, is already developing new therapies using the AAVs to target the central nervous system.

With more development, the scientists think it’s possible to improve the gene-delivery efficiency of their AAVs to the central nervous system, decrease their accumulation in the liver, and avoid inactivation by antibodies in some patients.

Sonia Vallabh and Eric Minikel, two researchers at the Broad who are developing treatments for prion disease, are excited by the potential of the AAVs to deliver brain therapies in humans.

“When we think about gene therapy for a whole-brain disease like prion disease, you need really systemic delivery and broad biodistribution in order to achieve anything,” said Minikel. “Naturally occurring AAVs just aren’t going to get you anywhere. This engineered capsid opens up a world of possibilities.”



Source link

Continue Reading
Click to comment

Leave a Reply

TOP SCEINCE

New drug shows promise in clearing HIV from brain

Published

on

By

New gene delivery vehicle shows promise for human brain gene therapy


An experimental drug originally developed to treat cancer may help clear HIV from infected cells in the brain, according to a new Tulane University study.

For the first time, researchers at Tulane National Primate Research Center found that a cancer drug significantly reduced levels of SIV, the nonhuman primate equivalent of HIV, in the brain by targeting and depleting certain immune cells that harbor the virus.

Published in the journal Brain, this discovery marks a significant step toward eliminating HIV from hard-to-reach reservoirs where the virus evades otherwise effective treatment.

“This research is an important step in tackling brain-related issues caused by HIV, which still affect people even when they are on effective HIV medication,” said lead study author Woong-Ki Kim, PhD, associate director for research at Tulane National Primate Research Center. “By specifically targeting the infected cells in the brain, we may be able to clear the virus from these hidden areas, which has been a major challenge in HIV treatment.”

Antiretroviral therapy (ART) is an essential component of successful HIV treatment, maintaining the virus at undetectable levels in the blood and transforming HIV from a terminal illness into a manageable condition. However, ART does not completely eradicate HIV, necessitating lifelong treatment. The virus persists in “viral reservoirs” in the brain, liver, and lymph nodes, where it remains out of reach of ART.

The brain has been a particularly challenging area for treatment due to the blood-brain barrier — a protective membrane that shields it from harmful substances but also blocks treatments, allowing the virus to persist. In addition, cells in the brain known as macrophages are extremely long-lived, making them difficult to eradicate once they become infected.

Infection of macrophages is thought to contribute to neurocognitive dysfunction, experienced by nearly half of those living with HIV. Eradicating the virus from the brain is critical for comprehensive HIV treatment and could significantly improve the quality of life for those with HIV-related neurocognitive problems.

Researchers focused on macrophages, a type of white blood cell that harbors HIV in the brain. By using a small molecule inhibitor to block a receptor that increases in HIV-infected macrophages, the team successfully reduced the viral load in the brain. This approach essentially cleared the virus from brain tissue, providing a potential new treatment avenue for HIV.

The small molecule inhibitor used, BLZ945, has previously been studied for therapeutic use in amyotrophic lateral sclerosis (ALS) and brain cancer, but never before in the context of clearing HIV from the brain.

The study, which took place at the Tulane National Primate Research Center, utilized three groups to model human HIV infection and treatment: an untreated control group, and two groups treated with either a low or high dose of the small molecule inhibitor for 30 days. The high-dose treatment lead to a notable reduction in cells expressing HIV receptor sites, as well as a 95-99% decrease in viral DNA loads in the brain .

In addition to reducing viral loads, the treatment did not significantly impact microglia, the brain’s resident immune cells, which are essential for maintaining a healthy neuroimmune environment. It also did not show signs of liver toxicity at the doses tested.

The next step for the research team is to test this therapy in conjunction with ART to assess its efficacy in a combined treatment approach. This could pave the way for more comprehensive strategies to eradicate HIV from the body entirely.

This research was funded by the National Institutes of Health, including grants from the National Institute of Mental Health and the National Institute of Neurological Disorders and Stroke, and was supported with resources from the Tulane National Primate Research Center base grant of the National Institutes of Health, P51 OD011104.



Source link

Continue Reading

TOP SCEINCE

Chemical analyses find hidden elements from renaissance astronomer Tycho Brahe’s alchemy laboratory

Published

on

By

New gene delivery vehicle shows promise for human brain gene therapy


In the Middle Ages, alchemists were notoriously secretive and didn’t share their knowledge with others. Danish Tycho Brahe was no exception. Consequently, we don’t know precisely what he did in the alchemical laboratory located beneath his combined residence and observatory, Uraniborg, on the now Swedish island of Ven.

Only a few of his alchemical recipes have survived, and today, there are very few remnants of his laboratory. Uraniborg was demolished after his death in 1601, and the building materials were scattered for reuse.

However, during an excavation in 1988-1990, some pottery and glass shards were found in Uraniborg’s old garden. These shards were believed to originate from the basement’s alchemical laboratory. Five of these shards — four glass and one ceramic — have now undergone chemical analyses to determine which elements the original glass and ceramic containers came into contact with.

The chemical analyses were conducted by Professor Emeritus and expert in archaeometry, Kaare Lund Rasmussen from the Department of Physics, Chemistry, and Pharmacy, University of Southern Denmark. Senior researcher and museum curator Poul Grinder-Hansen from the National Museum of Denmark oversaw the insertion of the analyses into historical context.

Enriched levels of trace elements were found on four of them, while one glass shard showed no specific enrichments. The study has been published in the journal Heritage Science.

“Most intriguing are the elements found in higher concentrations than expected — indicating enrichment and providing insight into the substances used in Tycho Brahe’s alchemical laboratory,” said Kaare Lund Rasmussen.

The enriched elements are nickel, copper, zinc, tin, antimony, tungsten, gold, mercury, and lead, and they have been found on either the inside or outside of the shards.

Most of them are not surprising for an alchemist’s laboratory. Gold and mercury were — at least among the upper echelons of society — commonly known and used against a wide range of diseases.

“But tungsten is very mysterious. Tungsten had not even been described at that time, so what should we infer from its presence on a shard from Tycho Brahe’s alchemy workshop?,” said Kaare Lund Rasmussen.

Tungsten was first described and produced in pure form more than 180 years later by the Swedish chemist Carl Wilhelm Scheele. Tungsten occurs naturally in certain minerals, and perhaps the element found its way to Tycho Brahe’s laboratory through one of these minerals. In the laboratory, the mineral might have undergone some processing that separated the tungsten, without Tycho Brahe ever realizing it.

However, there is also another possibility that Professor Kaare Lund Rasmussen emphasizes has no evidence whatsoever — but which could be plausible.

Already in the first half of the 1500s, the German mineralogist Georgius Agricola described something strange in tin ore from Saxony, which caused problems when he tried to smelt tin. Agricola called this strange substance in the tin ore “Wolfram” (German for Wolf’s froth, later renamed to tungsten in English).

“Maybe Tycho Brahe had heard about this and thus knew of tungsten’s existence. But this is not something we know or can say based on the analyses I have done. It is merely a possible theoretical explanation for why we find tungsten in the samples,” said Kaare Lund Rasmussen.

Tycho Brahe belonged to the branch of alchemists who, inspired by the German physician Paracelsus, tried to develop medicine for various diseases of the time: plague, syphilis, leprosy, fever, stomach aches, etc. But he distanced himself from the branch that tried to create gold from less valuable minerals and metals.

In line with the other medical alchemists of the time, he kept his recipes close to his chest and shared them only with a few selected individuals, such as his patron, Emperor Rudolph II, who allegedly received Tycho Brahe’s prescriptions for plague medicine.

We know that Tycho Brahe’s plague medicine was complicated to produce. It contained theriac, which was one of the standard remedies for almost everything at the time and could have up to 60 ingredients, including snake flesh and opium. It also contained copper or iron vitriol (sulphates), various oils, and herbs.

After various filtrations and distillations, the first of Brahe’s three recipes against plague was obtained. This could be made even more potent by adding tinctures of, for example, coral, sapphires, hyacinths, or potable gold.

“It may seem strange that Tycho Brahe was involved in both astronomy and alchemy, but when one understands his worldview, it makes sense. He believed that there were obvious connections between the heavenly bodies, earthly substances, and the body’s organs. Thus, the Sun, gold, and the heart were connected, and the same applied to the Moon, silver, and the brain; Jupiter, tin, and the liver; Venus, copper, and the kidneys; Saturn, lead, and the spleen; Mars, iron, and the gallbladder; and Mercury, mercury, and the lungs. Minerals and gemstones could also be linked to this system, so emeralds, for example, belonged to Mercury,” explained Poul Grinder-Hansen.

Kaare Lund Rasmussen has previously analyzed hair and bones from Tycho Brahe and found, among other elements, gold. This could indicate that Tycho Brahe himself had taken medicine that contained potable gold.



Source link

Continue Reading

TOP SCEINCE

Nitrogen emissions have a net cooling effect: But researchers warn against a climate solution

Published

on

By

New gene delivery vehicle shows promise for human brain gene therapy


An international team of researchers has found that nitrogen emissions from fertilisers and fossil fuels have a net cooling effect on the climate. But they warn increasing atmospheric nitrogen has further damaging effects on the environment, calling for an urgent reduction in greenhouse gas emissions to halt global warming.

Published today in Nature, the paper found that reactive nitrogen released in the environment through human activities cools the climate by minus 0.34 watts per square metre. While global warming would have advanced further without the input of human-generated nitrogen, the amount would not offset the level of greenhouse gasses heating the atmosphere.

The paper was led by the Max Planck Institute in Germany and included authors from the University of Sydney. It comes one day after new data from the European Union’s Copernicus Climate Change Service indicated that Sunday, 21 July was the hottest day recorded in recent history.

The net cooling effect occurs in four ways:

  • Short-lived nitrogen oxides produced by the combustion of fossil fuels pollute the atmosphere by forming fine suspended particles which shield sunlight, in turn cooling the climate;

  • ammonia (a nitrogen and hydrogen-based compound) released into the atmosphere from the application of manure and artificial fertilisers has a similar effect;

  • nitrogen applied to crops allows plants to grow more abundantly, absorbing more CO2 from the atmosphere, enabling a cooling effect;

  • nitrogen oxides also play a role in the breakdown of atmospheric methane, a potent greenhouse gas.

The researchers warned that increasing atmospheric nitrogen was not a solution for combatting climate change.

“Nitrogen fertilisers pollute water and nitrogen oxides from fossil fuels pollute the air. Therefore, increasing rates of nitrogen in the atmosphere to combat climate change is not an acceptable compromise, nor is it a solution,” said Professor Federico Maggi from the University of Sydney’s School of Civil Engineering.

Sönke Zaehle from the Max Planck Institute said: “This may sound like good news, but you have to bear in mind that nitrogen emissions have many harmful effects, for example on health, biodiversity and the ozone layer. The current findings, therefore, are no reason to gloss over the harmful effects, let alone see additional nitrogen input as a means of combatting global warming.”

Elemental nitrogen, which makes up around 78 percent of the air, is climate-neutral, but other reactive nitrogen compounds can have direct or indirect effects on the global climate — sometimes warming and at other times cooling. Nitrous oxide (N2O) is an almost 300 times more potent greenhouse gas than CO2. Other forms of nitrogen stimulate the formation of ozone in the troposphere, which is a potent greenhouse gas and enhances global warming.

Professor Maggi said the research was important as it helped the team gain an understanding of the net-effect of the distribution of nitrogen emissions from agriculture.

“This work is an extraordinary example of how complex interactions at planetary scales cannot be captured with simplistic assessment tools. It shows the importance of developing mathematical models that can show the emergence of nonlinear — or unproportional — effects across soil, land, and atmosphere,” he said.

“Even if it appears counter-intuitive, reactive nitrogen introduced in the environment, mostly as agricultural fertilisers, can reduce total warming. However, this is minor compared with the reduction in greenhouse gas emissions required to keep the planet within safe and just operational boundaries.

“New generation computational tools are helping drive new learnings in climate change science, but understanding is not enough — we must act with great urgency to reduce greenhouse gas emissions.”

Gaining a holistic understanding of the impacts of nitrogen

The scientists determined the overall impact of nitrogen from human sources by first analysing the quantities of the various nitrogen compounds that end up in soil, water and air.

They then fed this data into models that depict the global nitrogen cycle and the effects on the carbon cycle, for example the stimulation of plant growth and ultimately the CO2 and methane content of the atmosphere. From the results of these simulations, they used another atmospheric chemistry model to calculate the effect of man-made nitrogen emissions on radiative forcing, that is the radiant energy that hits one square metre of the Earth’s surface per unit of time.



Source link

Continue Reading

Trending